Literature DB >> 10675541

LOX-1 mediates lysophosphatidylcholine-induced oxidized LDL uptake in smooth muscle cells.

T Aoyama1, M Chen, H Fujiwara, T Masaki, T Sawamura.   

Abstract

A novel receptor for oxidized low-density lipoprotein (OxLDL), lectin-like OxLDL receptor (LOX-1), was cloned from endothelial cells. Since OxLDL is taken up by vascular smooth muscle cells (VSMC) in atheroma, we analyzed the inducible expression of LOX-1 in VSMC in the present study. Incubation of cultured bovine VSMC with lysophosphatidylcholine (LPC), an atherogenic component of OxLDL, increased the level of mRNA for LOX-1 in a dose- and time-dependent manner. Since LPC did not significantly change the half-life of LOX-1 mRNA, the induction seemed to occur at the transcriptional level. The induction accompanied an increase in the protein level of LOX-1 and activity of OxLDL uptake. Blocking antibody against LOX-1 significantly suppressed the enhanced uptake of OxLDL. Thus, LOX-1 is a major receptor for OxLDL in VSMC as in endothelial cells. The enhanced expression of LOX-1 by LPC suggests that OxLDL and LPC would progressively change the function of VSMC and accelerate atherogenesis in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10675541     DOI: 10.1016/s0014-5793(00)01154-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  33 in total

1.  Conserved C-terminal residues within the lectin-like domain of LOX-1 are essential for oxidized low-density-lipoprotein binding.

Authors:  M Chen; S Narumiya; T Masaki; T Sawamura
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

Review 2.  New scavenger receptors and their functions in atherogenesis.

Authors:  Noriaki Kume; Toru Kita
Journal:  Curr Atheroscler Rep       Date:  2002-07       Impact factor: 5.113

Review 3.  Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untested.

Authors:  J Thomas Grayston; Robert J Belland; Gerald I Byrne; Cho Chou Kuo; Julius Schachter; Walter E Stamm; Guangming Zhong
Journal:  Pathog Dis       Date:  2014-12-04       Impact factor: 3.166

Review 4.  Upregulated LOX-1 Receptor: Key Player of the Pathogenesis of Atherosclerosis.

Authors:  Sanjiv Singh; Avtar Singh Gautam
Journal:  Curr Atheroscler Rep       Date:  2019-07-27       Impact factor: 5.113

5.  LOX-1 augments oxLDL uptake by lysoPC-stimulated murine macrophages but is not required for oxLDL clearance from plasma.

Authors:  David F Schaeffer; Maziar Riazy; Kuljit S Parhar; Johnny H Chen; Vincent Duronio; Tatsuya Sawamura; Urs P Steinbrecher
Journal:  J Lipid Res       Date:  2009-04-09       Impact factor: 5.922

6.  Lectin-like Ox-LDL receptor is expressed in human INT-407 intestinal cells: involvement in the transcytosis of pancreatic bile salt-dependent lipase.

Authors:  Nadine Bruneau; Stéphane Richard; Françoise Silvy; Alain Verine; Dominique Lombardo
Journal:  Mol Biol Cell       Date:  2003-04-04       Impact factor: 4.138

7.  Expression and localization of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in murine and human placentas.

Authors:  Hiroo Satoh; Emi Kiyota; Yasuhiro Terasaki; Tatsuya Sawamura; Katsumasa Takagi; Hiroshi Mizuta; Motohiro Takeya
Journal:  J Histochem Cytochem       Date:  2008-05-12       Impact factor: 2.479

8.  Lysophosphatidylcholine upregulates LOX-1, chemokine receptors, and activation-related transcription factors in human T-cell line Jurkat.

Authors:  Yuko Hara; Yoshiaki Kusumi; Masako Mitsumata; Xiao-Kang Li; Masayuki Fujino
Journal:  J Thromb Thrombolysis       Date:  2007-10-26       Impact factor: 2.300

Review 9.  Role of oxidative stress-related biomarkers in heart failure: galectin 3, α1-antitrypsin and LOX-1: new therapeutic perspective?

Authors:  Valter Lubrano; Silvana Balzan
Journal:  Mol Cell Biochem       Date:  2019-11-29       Impact factor: 3.396

Review 10.  Lipoprotein receptor signalling in atherosclerosis.

Authors:  Chieko Mineo
Journal:  Cardiovasc Res       Date:  2020-06-01       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.